Clinical trials: Oxycodone
Management of Moderate to Severe Pain
Pharmacokinetics Study of ALO-02 and OxyContin
To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers
- Trial name
- NCT01557257
- Testing
- ALO-02, Naltrexone block, OxyContin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain, Back Pain
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the treatment of acute low back pain.
- Conditions
- Pain, Back Pain, Low Back Pain, Back Pain With Radiation
- Trial name
- NCT00986180
- Testing
- NUCYNTA, Oxycodone IR
- Where
- 74 sites in United States
- Volunteers
- 667 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Healthy
Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers
To Estimate Bioavailability Of 40 Mg Doses Of Pf-00345439 Formulation K Under Fasting Conditions with 40% Ethanol Compared with Water in Healthy Volunteers
- Trial name
- NCT02165930
- Testing
- Oxycodone, Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Parkinson's Disease With Severe Pain
A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain
To demonstrate superiority of OXN PR compared to placebo with respect to analgesic efficacy in subjects with chronic severe pain associated with Parkinson's disease (PD), as assessed by averaged 24 hour pain scores collected for…
- Trial name
- NCT01439100
- Testing
- Oxycodone/Naloxone Prolonged Release tablets
- Where
- 31 sites in Czechia, Germany and 5 more
- Volunteers
- 172 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Chronic Pain
An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)
Objectives: 1. Objective of main interest To assess the drop-out rate caused by adverse event* after 6 weeks treatment 2. Further objectives To assess the drop-out rate caused by adverse event* after 1 week treatment To assess…
- Trial name
- NCT01811186
- Testing
- Oxycodone/naloxone
- Where
- South Korea
- Volunteers
- 261 people
- Sponsor
- Mundipharma Korea Ltd
Pain, Cancer
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time; explores what the body does to…
- Trial name
- NCT00805142
- Testing
- Tapentadol PR
- Where
- 21 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Janssen Pharmaceutical K.K.
Opioid-Related Disorders
Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse
This is a single-center, randomized, 7-way crossover, double-blind, active and placebo-controlled study to evaluate the subjective effects of oxycodone combined with ultra-low dose naltrexone in comparison to oxycodone alone in…
- Trial name
- NCT00734461
- Testing
- oxycodone and naltrexone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Pain Therapeutics
Healthy
A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers
The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GL2907 XL 20mg tablet and Oxycontin CR 10mg tablet. GL2907 XL 20mg tablet is controlled released formulation which is made by GL Pharm Tech.
- Trial name
- GL2907-101 (NCT01568450)
- Testing
- Oxycodone
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Respiratory Depression
Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.
The purpose of this study is to explore and compare VRH after administration of Belbuca, Oxycodone HCl and Placebo in recreational opioid users.
- Trial name
- NCT03996694
- Testing
- Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- BioDelivery Sciences International
Hip or Knee Replacement
CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery
Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery.
- Trial name
- CBP0276-Opd (NCT07687966)
- Testing
- CBP-0276
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Clarent Biopharma, Inc.
Healthy Volunteers
Evaluation of Oral PF614 Relative to OxyContin (PF614-102)
This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B).
- Trial name
- NCT05043766
- Testing
- PF614, Naltrexone Hydrochloride, OxyContin
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Pain
Oxycodone-naloxone in Relieving Opioid-related Constipation
The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects…
- Trial name
- NCT00412152
- Testing
- Oxycodone nalaxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
The purpose of this study is to characterize the long-term safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid experienced pediatric patients aged 6 to 17 years, inclusive, with moderate to severe…
- Trial name
- NCT01369615
- Testing
- Oxycodone hydrochloride controlled-release tablets
- Where
- 14 sites in United States, Israel
- Volunteers
- 23 people
- Sponsor
- Purdue Pharma LP
Post Operative Pain
OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty
The purpose of this study is to demonstrate that treatment with OXN PR tablets is non inferior to treatment with OXY PR tablets in terms of analgesic efficacy in patients with postoperative pain after knee arthroplasty based on…
- Trial name
- OXN4505 (NCT01083485)
- Testing
- Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets, Oxycodone
- Where
- Finland
- Volunteers
- 137 people
- Sponsor
- Mundipharma Oy
Postoperative Pain
Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
- Trial name
- NCT00818493
- Testing
- Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- QRxPharma Inc.
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Pain
Dronabinol Opioid Sparing Evaluation (DOSE) Trial
This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients…
- Trial name
- NCT03766269
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Daisy Pharma Opioid Venture, LLC
Healthy Volunteers
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (10 mg) relative to the original OxyContin® (OXY) formulation (10 mg) in the fed state.
- Trial name
- NCT01099709
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Chronic Pain
Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain
Evaluate the efficacy of treatment with the fentanyl buccal tablet (FBT) compared with immediate release oxycodone treatment in alleviating breakthrough pain (BTP) in opioid tolerant patients with chronic pain.
- Trial name
- NCT00813488
- Testing
- Fentanyl Buccal Tablet, Immediate release oxycodone
- Where
- 50 sites in United States
- Volunteers
- 213 people
- Sponsor
- Cephalon
Healthy
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
- Trial name
- NCT00955110
- Testing
- Oxymorphone ER, Oxycodone CR, Hydromorphone
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company